Bliss GVS Pharma delivery percentage & share price.
· data for the trading session of Wed 18 Nov 2026
Price, volume and delivery
Candles adjusted for splits and bonuses. In the lower panel, the grey bar is the day’s volume and the coloured bar is the part that was delivered; bright green marks big-buyer days (delivered shares 3× the stock’s normal or more, with a normal-or-higher delivery %).
Bliss GVS Pharma share price today: what happened on 18 November
Written from NSE’s end-of-day data for 18 Nov 2026. Updated every trading evening. Facts, not advice.
Bliss GVS Pharma rose to ₹680.35 on Wednesday, 18 November 2026, up ₹24.00 or 3.66% from the previous close of ₹656.35. It opened at ₹660.90 and traded between ₹652.00 and ₹688.90, a range of 5.6% of its price, and finished in the middle of it. Among the 126 Pharma & healthcare stocks we track, it ranked 7th by today’s move; the typical stock in the sector moved -0.53%.
It closed higher on 6 of the last 10 sessions and is +9.8% over that stretch. Looking further back: one week +3.7%, one month +8.5%, three months +18.6%, one year +310.1%. Its relative strength (RS) rating is 99 on a 1–99 scale, which means its 12-month performance beats about 99% of the 1,443 most traded NSE stocks.
2.58 lakh shares changed hands, worth about ₹17.4 crore, 1.4 times the 20-session average. Of those, 0% (0 shares) were taken for delivery, meaning they actually changed owners instead of being traded within the day. That compares with a 60-session average of 0%. There were no big-buyer days (delivery several times above normal) in the last three months.
The close is 2.2% above the 50-day average of ₹665.93 and 55.4% above the 200-day average of ₹437.81. The 14-day RSI, a 0–100 gauge of recent momentum, reads 57, in the neutral zone between 30 and 70. It sits 8.0% below its 52-week high of ₹739.90 and 383.2% above the low of ₹140.80, in the upper part of the year’s range.
Looking at where shares were actually delivered over the past year, the busiest price zone below today’s close is around ₹427 (-37.2%). Prices often slow down near such zones because many holders bought there, but they are history, not predictions.
NSE has it under surveillance (Long-term ASM Stage IV), which can mean tighter trading rules.
On a typical day Bliss GVS Pharma moves about ±3.6%, and its average session spans 5.0% from high to low. It closed higher on 55% of the sessions in the past year. It opened with a gap of 1% or more 79 times in that year (45 up, 34 down). Its best day of the year was 26 May 2026 (+20.00%) and its worst was 10 December 2025 (-7.52%).
Last five sessions
| Day | Close | Change | Volume | Delivery |
|---|---|---|---|---|
| Wed 18 Nov | ₹680.35 | +3.66% | 2.58 lakh | 0% |
| Tue 17 Nov | ₹656.35 | -0.52% | 63,138 | 0% |
| Mon 16 Nov | ₹659.80 | -1.98% | 1.26 lakh | 0% |
| Fri 13 Nov | ₹673.10 | +4.92% | 4.09 lakh | 0% |
| Thu 12 Nov | ₹641.55 | -2.25% | 74,214 | 0% |
Price levels by delivered volume
Where the most Bliss GVS Pharma shares were actually delivered over the last year. Each day’s delivered shares are spread across that day’s high–low range; the peaks are the busiest price zones. Below the close: support zones; above: resistance zones. History, not a forecast.
- Last close₹680.3518 Nov
- Support 1₹427-37.2% · 4.2% of the year’s delivery
- Support 2₹276-59.4% · 9.9% of the year’s delivery
- Support 3₹215-68.3% · 12.1% of the year’s delivery
Bliss GVS Pharma score
Ranked 0–100 against 1,356 NSE stocks (prices of 18 Nov 2026). Relative ranks for learning, not advice.
Passes 10 of 15 checks on the 18-point checklist.
See how Bliss GVS Pharma’s scores are made and the full checklist →Bliss GVS Pharma at a glance
- Bliss GVS Pharma closed at ₹680.35 on 18 Nov 2026 (+3.66% on the day). Over the past year it is +310.07%, against -2.39% for NIFTY 50.
- It trades 8.0% below its 52-week high of ₹739.90 and 383.2% above its low of ₹140.80.
- 0% of the shares traded on 18 Nov were delivered, against a 60-session average of 0%.
- There were no big-buyer days (delivery far above normal) in the last three months.
- A typical day moves it about ±3.6%: more volatile than 92% of the 1,443 most traded NSE stocks.
- Fundamentals: P/E 44.7 · Profit +92% YoY.
Bliss GVS Pharma company details
From the exchanges’ own records: NSE and BSE listings and their industry classification.
- Sector
- Pharma & healthcare
- Industry
- Pharmaceuticals
- Macro sector
- Healthcare
- ISIN
- INE416D01022
- NSE symbol
- BLISSGVS
- BSE code
- 506197
- Listed on NSE since
- 26 July 2010
- Face value
- ₹1 per share
Bliss GVS Pharma pros and cons
Written automatically from the latest results, shareholding, valuation against its sector, and price and delivery data. Facts, not advice.
Pros
- Almost debt-free: borrowings are under 10% of equity.
- Profit has grown for 3 quarters in a row.
- Profit up 92% on a year ago (quarter ended Sep 2026).
- Sales up 28% on a year ago.
- Promoters raised their holding by 15.06 points, to 50.1%.
- Relative strength rating 99 out of 99: it has outperformed most stocks over the past year.
Cons
- Foreign investors (FIIs) cut their stake by 3.0 points last quarter, to 5.0%.
- More volatile than 92% of the most traded NSE stocks.
Bliss GVS Pharma stock DNA
Where Bliss GVS Pharma sits among the 1,443 most traded NSE stocks, on a 0–100 scale: 0 is the lowest of all of them, 100 the highest. From the last year of daily data. The first row is the RS rating used on our relative strength ranking.
How Bliss GVS Pharma usually moves
Every session of the last year by size of move. The white line is the last session.
Best day 26 May 2026 (+20.00%), worst 10 Dec 2025 (-7.52%).
Bliss GVS Pharma vs NIFTY 50, one year
Both start at 100. The shaded gap is how far Bliss GVS Pharma is ahead of or behind the market.
Bliss GVS Pharma fundamentals
Quarterly results and shareholding from NSE filings. Profit is the share owed to the company’s own shareholders. Compare in the stock screener →
Revenue
₹ crore per quarter (consolidated); L = lakh crore, k = thousand crore.
Net profit
₹ crore per quarter (consolidated); L = lakh crore, k = thousand crore.
Who owns Bliss GVS Pharma
Shareholding pattern for the quarter to 30 Sep 2026, from the company’s filing with NSE.
Change since Jun 2026:
Promoter holding over time
Promoter and promoter group stake, every quarter.
Bliss GVS Pharma balance sheet, returns and cash flow
From the consolidated half-year and annual results filed with NSE (latest: 30 Sep 2026), on the same basis as the quarterly figures above.
| Sep 2025half year | Mar 2026full year | Sep 2026half year | |
|---|---|---|---|
| Shareholders’ equity | ₹1,132 Cr | ₹1,193 Cr | ₹1,290 Cr |
| Borrowings (excl. leases) | ₹36.0 Cr | ₹2.9 Cr | ₹0.0 Cr |
| Cash, bank balances & current investments | ₹201 Cr | ₹168 Cr | ₹151 Cr |
| Operating cash flow | ₹77.5 Cr | ₹139 Cr | ₹35.7 Cr |
| Capex (PPE + intangibles) | ₹29.2 Cr | ₹56.8 Cr | ₹31.7 Cr |
Balance sheet items are as at the date shown; cash flows cover the half year or full year to that date. ₹ crore.
Bliss GVS Pharma vs peers
Bliss GVS Pharma is number 70 of 121 Pharma & healthcare companies by market cap. The table shows it with the 7 companies nearest to it in size. P/E is on the last four quarters’ profit, growth compares the latest quarter with a year earlier, Q / V / M are ChartMine scores (quality, valuation, momentum, 0–100) for 17 Nov 2026. Tap a column heading to sort.
| Thyrocare Technologies | 503.60 | 8,016 | 56.0 | 14.5 | 26.2 | 25% | −68% | 6% | −5% | 89 | 37 | 53 |
| Suven Life Sciences | 265.65 | 7,507 | – | 16.6 | −104.0 | 30% | – | – | 49% | 24 | – | 50 |
| Sanofi India | 3,232 | 7,433 | 20.4 | 9.0 | 44.1 | 3% | 54% | 24% | −29% | 81 | 63 | 43 |
| Bliss GVS Pharma | 680.35 | 7,232 | 44.7 | 5.6 | 13.3 | 28% | 92% | 17% | 310% | 73 | 47 | 84 |
| NEPHROPLUS | 653.00 | 6,566 | 50.3 | 5.5 | 10.8 | – | – | 11% | – | 52 | 45 | 67 |
| SPARC | 190.12 | 6,169 | 3.8 | 4.3 | 113.4 | 282% | – | −81% | 46% | 78 | 56 | 64 |
| FDC | 373.90 | 6,087 | 19.4 | 2.3 | 12.3 | 21% | 73% | 9% | −9% | 58 | 69 | 61 |
| Innova Captab | 1,050 | 6,010 | 36.0 | 5.1 | 15.2 | 30% | 43% | 9% | 43% | 58 | 50 | 61 |
| Sector median | – | 9,495 | 42.0 | 4.5 | 13.3 | 21% | 26% | 12% | 12% | 54 | 47 | 64 |
Sector: Pharma & healthcare (126 companies). Medians are over every Pharma & healthcare company with that figure. ₹ crore; market cap at the last close.
Bliss GVS Pharma cash flow
Cash generated by the business, spent on investment and returned to or raised from investors, by fiscal year (consolidated figures from the annual results). Operating cash flow covered profit in 2 of the last 2 years. Free cash flow was positive in 2 of 2 years.
| Year | Operating cash flow | Investing | Financing | Capex | Free cash flow | Profit | Cash conversion | Dividends paid |
|---|---|---|---|---|---|---|---|---|
| FY26 | 139 | −38 | −89 | 57 | 82 | 135 | 103% | 11 |
| FY25 | 106 | −75 | −30 | 76 | 30 | 90 | 117% | 5 |
₹ crore. Free cash flow = operating cash flow − capex. Cash conversion = operating cash flow ÷ profit. Capex and dividends are cash paid out.
Operating cash flow vs profit
₹ crore by fiscal year. When the blue bar is taller than the green one, the business turned more than its reported profit into cash.
Bliss GVS Pharma dividend history, bonus and splits
From NSE’s corporate-action records since 2005. Prices on this page are already adjusted for splits and bonuses.
Bliss GVS Pharma dividend history
Total declared per share in each year, as announced (not adjusted for later splits or bonuses). Last 12 months: ₹1.5 a share, a 0.22% yield at today’s price.
| Year | Dividend per share | Payouts |
|---|---|---|
| 2026 | ₹1.5 | 2 |
| 2025 | ₹0.5 | 1 |
| 2024 | ₹0.5 | 1 |
| 2023 | ₹0.5 | 1 |
| 2022 | ₹0.5 | 1 |
| 2021 | ₹0.5 | 1 |
| 2020 | ₹0.5 | 1 |
| 2019 | ₹1 | 1 |
| 2018 | ₹1 | 1 |
| 2017 | ₹0.6 | 1 |
| 2016 | ₹0.5 | 1 |
| 2015 | ₹0.7 | 2 |
Latest: Dividend ₹1 (ex 8 Jul 2026); Interim ₹0.5 (ex 18 Feb 2026); Dividend ₹0.5 (ex 24 Jul 2025); Dividend ₹0.5 (ex 18 Jul 2024).
Delivery and big-buyer days
Delivered shares change owners for real; intraday trades don’t. Days when delivery jumps far above normal often mean large investors were buying or selling.
Delivery calendar, last 12 months
Each square is a session. The brighter the green, the more shares were delivered compared with Bliss GVS Pharma’s normal. Hover or tap a square for the day.
Latest big-buyer days
What the price did on the day and five sessions later. Past moves only.
| Date | Delivered | vs normal | Delivery % | Day | 5 days later |
|---|---|---|---|---|---|
| 25 May 2026 | 33.57 L | 5.8× | 34% | +5.73% | +36.81% |
| 14 May 2026 | 19.34 L | 3.7× | 44% | +3.52% | +2.00% |
| 13 Feb 2026 | 16.70 L | 3.8× | 25% | -0.17% | +2.50% |
| 12 Feb 2026 | 18.41 L | 4.2× | 30% | +1.86% | +3.79% |
| 11 Feb 2026 | 24.52 L | 5.6× | 26% | +2.96% | +7.37% |
| 10 Feb 2026 | 22.81 L | 5.3× | 23% | +2.20% | +11.12% |
| 9 Feb 2026 | 24.59 L | 5.7× | 27% | +11.14% | +9.02% |
| 29 Jan 2026 | 17.88 L | 5.0× | 25% | +9.18% | +0.63% |
Bliss GVS Pharma timeline
Everything that happened to Bliss GVS Pharma, newest first: deals, promoter filings, results, big-buyer days, new highs and big moves.
- October 2026
- 27 OctLarge holder Catalyst Trusteeship Limited Acting As Debenture Trustee On Behalf Of Debenture Holders bought 5.10 Cr shares47.95% of the company (off market / other); holds 47.95% after. Filed with NSE.
- 8 OctPromoter Anupam Rasayan India Ltd bought 5.10 Cr shares47.95% of the company (off market / other); holds 51.61% after. Filed with NSE.
- August 2026
- 19 AugNew 52-week high at ₹573.80First new high in 36 sessions.
- July 2026
- 8 JulDividend - Re 1 Per ShareEx-date: buy before this day to be entitled. From NSE’s corporate actions.
- May 2026
- 26 MayJumped 20.0% in one sessionClosed at ₹381.05, about 5.5× a normal day’s move.
- 25 MayBig-buyer day: 33.57 L shares delivered, 5.8× normal34% of the day’s volume was delivered; the price closed +5.73%.
- 14 MayBig-buyer day: 19.34 L shares delivered, 3.7× normal44% of the day’s volume was delivered; the price closed +3.52%.
- April 2026
- 7 AprNew 52-week high at ₹245.00First new high in 31 sessions.
- February 2026
- 18 FebInterim Dividend - Re 0.50 Per ShareEx-date: buy before this day to be entitled. From NSE’s corporate actions.
- 13 FebBig-buyer day: 16.70 L shares delivered, 3.8× normal25% of the day’s volume was delivered; the price closed -0.17%.
- 12 FebBig-buyer day: 18.41 L shares delivered, 4.2× normal30% of the day’s volume was delivered; the price closed +1.86%.
- 11 FebBig-buyer day: 24.52 L shares delivered, 5.6× normal26% of the day’s volume was delivered; the price closed +2.96%.
- 10 FebBig-buyer day: 22.81 L shares delivered, 5.3× normal23% of the day’s volume was delivered; the price closed +2.20%.
- 9 FebBig-buyer day: 24.59 L shares delivered, 5.7× normal27% of the day’s volume was delivered; the price closed +11.14%.
- 9 FebNew 52-week high at ₹205.80First new high in 22 sessions.
- 9 FebJumped 11.1% in one sessionClosed at ₹203.60, about 3.1× a normal day’s move.
- January 2026
- 29 JanBig-buyer day: 17.88 L shares delivered, 5.0× normal25% of the day’s volume was delivered; the price closed +9.18%.
- 6 JanNew 52-week high at ₹192.00First new high in over 20 sessions.
- 6 JanJumped 13.8% in one sessionClosed at ₹182.48, about 3.8× a normal day’s move.
- December 2025
- 10 DecBig-buyer day: 7.40 L shares delivered, 5.2× normal34% of the day’s volume was delivered; the price closed -7.52%.
- 1 DecBig-buyer day: 4.48 L shares delivered, 3.5× normal48% of the day’s volume was delivered; the price closed -6.15%.
- August 2025
- 20 AugBig-buyer day: 13.38 L shares delivered, 7.8× normal27% of the day’s volume was delivered; the price closed -4.41%.
- July 2025
- 24 JulAnnual General Meeting/Dividend - Rs 0.50 Per ShareEx-date: buy before this day to be entitled. From NSE’s corporate actions.
- June 2025
- 27 JunBig-buyer day: 6.05 L shares delivered, 3.8× normal41% of the day’s volume was delivered; the price closed +5.96%.
My notes on Bliss GVS Pharma
Private: saved only in this browser, never sent to us.
Questions
What is the 52-week high and low of Bliss GVS Pharma?
What is the delivery percentage of Bliss GVS Pharma?
How volatile is Bliss GVS Pharma?
What is the market cap of Bliss GVS Pharma?
What is the P/E ratio of Bliss GVS Pharma?
Who owns Bliss GVS Pharma? What is its shareholding pattern?
How were Bliss GVS Pharma's latest quarterly results?
What is the ROE of Bliss GVS Pharma?
Is Bliss GVS Pharma debt free?
What is the book value of Bliss GVS Pharma?
Who are Bliss GVS Pharma’s peers?
Does Bliss GVS Pharma generate cash?
Has Bliss GVS Pharma given bonus shares or split its stock?
Does Bliss GVS Pharma pay dividends?
What are the support and resistance levels of Bliss GVS Pharma?
What is the ISIN of Bliss GVS Pharma?
Data from NSE’s daily files, adjusted for splits and bonuses. Past behaviour is not a forecast. This is information, not investment advice; ChartMine is not a SEBI-registered adviser.
